Drug intelligence / Profile preview

SRx-T003

Development stage: Preclinical
Lead developer: Sania Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intramuscular

Overview

SRx-T003 is an adeno-associated virus (AAV)-based gene therapy developed by Sania Therapeutics. It is being investigated for the treatment of neurological disorders, with a primary focus on muscle spasticity and other nervous system diseases. The therapy is administered via intramuscular injection and aims to address underlying genetic or molecular causes of neuromuscular dysfunction. As of early 2025, SRx-T003 remains in preclinical development[1][2].

Beyond the preview

Go deeper on SRx-T003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRx-T003.

Explore the full profile